Skip to main content
. 2020 Sep 11;20(5):227. doi: 10.3892/ol.2020.12090

Figure 4.

Figure 4.

Expression of BCLAF1 is associated with USP22 expression in A549/DDP cells. (A) The expression levels of USP22 and BCLAF1 were measured and quantified in A549/WT and A549/DDP cells by western blotting. Cells were transfected with either control or BCLAF1 siRNA for 48 h. (B) USP22 mRNA expression was measured using reverse transcription- quantitative PCR in A549/WT cells transfected with siCTRL or siBCLAF1 and A549/DDP cells transfected with siCTRL. (C) The expression level of USP22 was measured in A549/DDP cells by western blotting. Cells were transfected with either control or USP22 siRNA for 48 h. (D) Representative immunofluorescence images of γH2AX and USP22 in A549/WT and A549/DDP cells transfected with siUSP22 or siCTRL. Cells were treated with 4 µM cisplatin for 10 h. Magnification, ×600. (E) Quantification of γH2AX and USP22 fluorescence intensity in A549/WT and A549/DDP cells transfected with siUSP22 or siCTRL. Data are presented as the means ± SD from three independent experimental repeats. *P<0.05, **P<0.01. DDP, cisplatin resistance; WT, wild-type; BCLAF1, bcl-2-associated transcription factor 1; si, small interfering; CTRL, control; γH2AX, γH2A histone family member X; USP22, ubiquitin-specific peptidase 22.